OTL38 in Imaging Patients with Suspected Pituitary Adenoma Undergoing Surgery

This phase I trial studies whether fluorescent imaging ligand OTL38 (OTL38) can identify pituitary adenomas during surgery in patients undergoing surgery for suspected pituitary adenomas. Pituitary gland adenomas are benign tumors, but can cause problems because of their size and proximity to the brain, and because of the hormones they can make. Fluorescent imaging ligand OTL38 may cause the tissue of the tumor to glow, and allow it to be seen by doctors using special cameras. This may allow the doctors to make sure the entire tumor is removed during surgery, and may allow them to find other tumors that were not previously identified.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02629549.

Trial PhasePhase I

Trial Typediagnostic

Lead OrganizationUniversity of Pennsylvania/Abramson Cancer Center

Principal InvestigatorSunil Singhal

• Primary IDUPCC 18315
• Secondary IDsNCI-2015-01600, NCT02769533, 822782
• ClinicalTrials.gov IDNCT02629549